Business - October 19, 2022
An end-to-end neurocentric company
This up-and-coming star on the global biotech scene aims to crack the hard code of finding better treatments for neurodegenerative diseases. The name of the company, Muna, means “to remember” in Old Norse and reflects the focus of discovering and developing medicines for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Multiple Sclerosis and Frontotemporal Dementia. These are […]
Business - October 11, 2022
Unlocking the full value potential in digital pathology
DoMore Diagnostics, one of our NLS Stars 2022, aims to change the one-size-fits-all approach in cancer therapy. Cancer is a growing global public health problem, and the cost of cancer care is expected to double the next 20 years. It is a leading cause of death worldwide and accounted for nearly 10 million deaths in […]
Business - September 30, 2022
Umeå Biotech Incubator launches international incubator program
Umeå Biotech Incubator (UBI) is launching the ‘UBI International Coaching Program’, with the first course starting on October 24th. “If you strive to be one of the world’s best incubators you must have the whole world as your marketplace”, says Jennie Ekbeck, CEO of UBI. “Our role is to help companies develop solutions that meet […]
Business - September 29, 2022
Q&A: Kaiku Health – from startup to acquisition
Two years ago Finnish health tech company Kaiku Health was acquired by Elekta, the global leader in radiotherapy technology. NLS asked Lauri Sippola, co-founder and CEO of Kaiku Health, about the company’s journey and his best advice to other entrepreneurs. Kaiku Health, based in Helsinki, is a great example of Finnish strengths in nurturing and […]
Biotech Business - August 31, 2022
Interview: Erik Manting, CEO, Mendus
Earlier this summer Immunicum announced a corporate rebranding and name change to Mendus and most recently the company reported financing commitments totaling up to 250 million SEK. NLS asked Erik Manting, CEO, about what lies ahead. What opportunities do you have on the market for cancer immunotherapy? “Many cancer patients today experience an initial treatment […]
Business - May 18, 2022
Business Interview: At the forefront of clinical cell therapy
XNK Therapeutics recently secured a private placement of 132 million SEK, enabling progress of the company’s development of new NK cell-based therapies. Since its foundation ten years ago, Swedish XNK Therapeutics has been developing novel autologous natural killer (NK) cell-based therapies targeting cancer. The company’s technology platform includes assets related to the investigational drug product […]
